IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Biotechnology

Healthcare
$26.49 -1.45%

-$0.45 today

Market cap
$2.56B
Beta
-0.05
P/E (TTM)
-19.5
EPS (TTM)
-$1.58
52W Low $20.50High $39.28

Volume 1.45M

Average 1.44M

IDYA Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

IDEAYA Biosciences, Inc.NASDAQ: IDYA

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity falls 8.5% from a year ago

Total equity stood at $937.27M at the end of Q1 FY2026, down 8.5% from a year earlier and down 8.4% from the prior quarter. Over 3 fiscal years it compounded at +43.0% a year.

Context

  • Total equity amounted to 91.0% of total assets at the end of Q1 FY2026, down 2.1 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -8.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$937.27M-8.4% QoQ
Last fiscal yearDec 2025
$1.02B-3.4% YoY
Year agoMar 2025
$1.02B-8.5% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.5%——
1 year-3.4%——
3-year CAGR+43.0%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
1.02B USD
Year-over-year change
-3.4%
4-year CAGR
+35.7%

Total Equity vs competitors

How IDYA compares with its peers on the latest reported figures

  • IDYA's Mar 2026 total equity of $937.27M is the 4th highest of the 9 companies compared; the peer median is $724.56M.
  • Its year-over-year change of -8.5% is the 7th highest of 9, against a peer median of +161.8%.
  • Total equity amounts to 91.0% of total assets for IDYA, versus a peer median of 62.0%.
IDYA Competitors Peer median
Total Equity for IDYA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RVMDRevolution Medicines, Inc.Jun 2026$2.61B +39.7%+33.5%60.3%
TNGXTango Therapeutics, Inc.Sep 2026$980.17M +512.5%+11.5%94.8%
NRIXNurix Therapeutics, Inc.Aug 2026$968.31M +160.1%+21.1%81.0%
IDYAIDEAYA Biosciences, Inc.Mar 2026$937.27M -8.5%+43.0%91.0%
ERASErasca, Inc.Sep 2026$916.74M +163.5%-7.6%91.8%
COGTCogent Biosciences, Inc.Jun 2026$532.39M +243.4%+35.5%63.8%
VSTMVerastem, Inc.Mar 2026$81.78M +352.1%+6.5%35.9%
PRLDPrelude Therapeutics IncorporatedMar 2026$60.18M -41.7%-29.4%50.3%
FHTXFoghorn Therapeutics Inc.Mar 2026-$76.41M -23.9%—34.4%
Peer median (excluding IDYA) $724.56M+161.8%+11.5%62.0%

Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents92.05M68.63M157.02M84.38M112.83M
Short-term Investments154.72M296.2M368.1M591.94M526.56M
Net Receivables1.1M211K18K3K5.97M
Inventory00000
Other Current Assets05.41M7.5M13.39M21.37M
Total Current Assets251M370.45M532.63M689.71M666.73M
Property, Plant & Equipment (Net)8.66M8.99M8.41M27.74M31.29M
Goodwill00000
Intangible Assets00000
Long-term Investments121.29M8.32M107.49M405.83M410.3M
Tax Assets00000
Other Non-current Assets397K205K782K805K1.02M
Total Non-current Assets130.35M17.52M116.68M434.38M442.6M
Total Assets381.35M387.97M649.32M1.12B1.11B
Account Payables2.1M4.28M6.6M15.42M17.58M
Short-term Debt0000339K
Tax Payables00000
Deferred Revenue29.04M8.57M000
Other Current Liabilities0011.78M30.35M29.69M
Total Current Liabilities45.16M31.72M27.1M46.07M58.82M
Long-term Debt000027.58M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)31.19M5.19M000
Other Non-current Liabilities00000
Total Non-current Liabilities34.67M6.8M1.13M18.87M27.58M
Total Liabilities79.83M38.51M28.23M64.94M86.39M
Common Stock4K5K7K9K9K
Retained Earnings(176.75M)(235.4M)(348.36M)(622.84M)(736.54M)
Accumulated OCI(712K)(2.87M)562K812K2.27M
Other Stockholders Equity00000
Minority Interest00000
Total Equity301.51M349.46M621.09M1.06B1.02B
Total Debt5.18M3.48M2.87M19.17M27.91M
Net Debt(86.87M)(65.15M)(154.15M)(65.21M)(84.91M)

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Intrinsic Alpha fair value

Locked

Current Price

$26.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.